EMAIL THIS PAGE TO A FRIEND

Vaccine

Therapeutic efficacy of the multi-epitope vaccine CTB-UE against Helicobacter pylori infection in a Mongolian gerbil model and its microRNA-155-associated immuno-protective mechanism.


PMID 25093281

Abstract

Vaccination is an effective means of preventing infectious diseases, including those caused by Helicobacter pylori. In this study, we constructed a novel multi-epitope vaccine, CTB-UE, composed of the cholera toxin B subunit and tandem copies of the B and Th cell epitopes from the H. pylori urease A and B subunits. We evaluated the therapeutic efficacy of the multi-epitope vaccine CTB-UE against H. pylori infection in a Mongolian gerbil model and studied its immuno-protective mechanisms. The experimental results indicated that urease activity, H. pylori colonisation density, the levels of IL-8 and TNF-α in the serum, and the levels of COX-2 and NAP in gastric tissue were significantly lower and the IgG level in the serum and the IFN-γ level in spleen lymphocytes were significantly higher in the vaccinated group compared with the model control group; additionally, gastric mucosal inflammation was notably alleviated following vaccination. The results showed that CTB-UE had a good therapeutic effect on H. pylori infection. The immuno-protective mechanism was closely related to the immune response mediated by microRNA-155, the expression of which was strongly up-regulated after CTB-UE administration. The expression levels of the microRNA-155 target proteins IFN-γRα, AID, and PU.1 were significantly down-regulated; these results indicated that CTB-UE induced an immune response biased towards Th1 cells by up-regulating microRNA-155 to inhibit IFN-γRα expression and induced a humoral immune response towards B cells by up-regulating microRNA-155 to inhibit PU.1 and AID expression. These results demonstrate that the multi-epitope vaccine CTB-UE may be a promising therapeutic vaccine against H. pylori infection and is a new therapeutic tool for human use.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB1411143
Anti-AICDA antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB2500040
Anti-AID antibody produced in goat, affinity isolated antibody, buffered aqueous solution
PRS3091
Anti-AID antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2101412
Anti-MAF (ab1) antibody produced in rabbit, affinity isolated antibody
SAB2101413
Anti-MAF (ab2) antibody produced in rabbit, affinity isolated antibody
HPA028289 Anti-MAF antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2500842
Anti-PU.1 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
AV37890
Anti-SFPI1 antibody produced in rabbit, IgG fraction of antiserum
AV31421
Anti-SPI1 antibody produced in rabbit, affinity isolated antibody
SAB2102283
Anti-SPI1 antibody produced in rabbit, affinity isolated antibody
HPA044653
Anti-SPI1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4502840
Anti-SPI1 antibody produced in rabbit, affinity isolated antibody
WH0004094M1
Monoclonal Anti-MAF antibody produced in mouse, clone 6B6, purified immunoglobulin, buffered aqueous solution
WH0006688M1
Monoclonal Anti-SPI1 antibody produced in mouse, clone 1A3, purified immunoglobulin, buffered aqueous solution
SAB1404402
Monoclonal Anti-SPI1, (N-terminal) antibody produced in mouse, clone 2G1, purified immunoglobulin, buffered aqueous solution